Clinical Outcome of Vinpocetine in Diabetic Nephropathy
The Effect of Vinpocetine on the Clinical Outcome of Patients With Diabetic Nephropathy
Ain Shams University
64 participants
Jul 10, 2024
INTERVENTIONAL
Conditions
Summary
The goal of this controlled, randomized, clinical trial is to evaluate the effect of vinpocetine on clinical outcomes on the diabetic nephropathy patients. The following will be evaluated; anthropometrics, kidney functions, glucose panel, lipid panel, ICAM-1, quality of life. Participants will receive either vinpocetine or placebo, twice daily for 3 months.
Eligibility
Inclusion Criteria4
- Age ≥ 18 years,
- Type II diabetic patients with CKD stage 3 (eGFR = 30 - 59 ml/min) or stage 4 (eGFR 15-29 ml/min),
- Albumin/Creatinine ratio (ACR): 30 - 300 μg /mg (microalbuminuria),
- Stable standard therapy for at least three months prior to inclusion in the study.
Exclusion Criteria8
- Kidney donor or recipient,
- Active malignancy,
- Pregnancy or breastfeeding,
- Known intolerance or hypersensitivity to VPN,
- Participation in other interventional trials,
- Patients with inadequate liver function (ALT and AST three times greater than the upper normal limits),
- Patients with severe comorbidities
- Patients receiving warfarin
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Vinca derivative of apovincamine, phosphodiestrase 1 inhibitor, sodium-gated voltage channel
Anti-hypertensive and anti-diabetic medications according to the the institution's protocol
Starch-filled capsules, matching those of the intervention
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06441591